Perspective Therapeutics Q2 2024 GAAP EPS $(0.18) Beats $(0.21) Estimate, Sales $526.000K Beat $158.667K Estimate
Portfolio Pulse from Benzinga Newsdesk
Perspective Therapeutics (AMEX:CATX) reported Q2 2024 GAAP EPS of $(0.18), beating the $(0.21) estimate. Sales were $526K, surpassing the $158.667K estimate but down 71.34% from $1.835M last year.
August 12, 2024 | 8:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Perspective Therapeutics reported better-than-expected Q2 2024 GAAP EPS of $(0.18) and sales of $526K, significantly beating estimates. However, sales decreased by 71.34% YoY.
The better-than-expected EPS and sales figures are positive for CATX in the short term, despite the significant YoY sales decline. The market is likely to react favorably to the earnings beat.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100